Dr. Hahn's research interests lie in translational work focused on the complex interplay between mental illness, antipsychotic treatments, and cardiometabolic risk, with a special interest in diabetes. Given the early accrual of metabolic risk leading to a 20% reduction in life expectancy for patients with schizophrenia, she has an interest in early episode individuals and prevention strategies. She currently is the principal investigator on a clinical trial examining a pharmacological intervention for younger patients with psychosis and glucose abnormalities. She co-leads the Mental Health and Metabolic Clinic at the CAMH, which specializes in metabolic monitoring, and interventions for metabolic risk factors in individuals with serious mental illness. From a translational perspective, Dr. Hahn oversees a basic science laboratory that studies underlying mechanisms of antipsychotic-related metabolic disturbances and their attenuation.
-Honours degree Biochemistry, McGill University (2001)
-MD, University of Calgary (2004)
-FRCPC, Psychiatry, Dalhouise University (2009)
-PhD, Institute of Medical Sciences, University of Toronto (2013)
-Fellowship in Schizophrenia Division, Center for Addiction and Mental Health (2013)
-Co-director, Mental Health and Metabolic Clinic, CAMH
-Staff psychiatrist, Complex Mental Illness, Division of Schizophrenia, CAMH